Wilson Portraits Unveiled
In Dedication Ceremony

Portraits of Luke and Helen Wilson, the Bethesda citizens who donated part of their "Tree Tops" estate to the U.S. Government in 1935—which eventually became NIH—were unveiled in Wilson Hall, Shannon Bldg., Dec. 18.

President Franklin D. Roosevelt, who received the original letter from Mr. Wilson and who made the final decision to locate NIH in Bethesda, publicly thanked the Wilsons in 1940 when he dedicated the original buildings of this campus. He said:

"For the very beautiful and very spacious grounds on which these buildings stand we are indebted to Mr. and Mrs. Luke Wilson, who wrote to me in 1935 asking if a part of their estate at Bethesda in Maryland could be used to the benefit of the people of this nation. I would tell her now as she sits beside me that in the compassion of Mr. and Mrs. Wilson

(See PORTRAITS, page 5)

Dr. Dawid Explores 'New Approaches to Old Questions' About Embryo Development for Mider Lecture

For nearly a century, scientists studying development have puzzled over how a single, fertilized egg cell develops into an organism made up of thousands of specialized cell types organized into arms and legs or a heart and brain. But the tools of the time taught these scientists little about the biological events underlying this seemingly miraculous process.

Although questions about how an embryo develops have changed little over the decades, new tools have generated new ideas about the way molecules and mechanisms shape up from a formless ball of cells into breathing, thinking, complex animals. At this year's G. Burroughs Mider lecture, developmental biologist Dr. Igor B. Dawid will explore how recombinant DNA technology and cell biology techniques have provided new ways to tackle these old questions.

He will deliver the lecture on Wednesday, Feb. 11, in the NIH Clinical Center's Masur Auditorium at 8:15 p.m.

As chief of the NICHD's Laboratory of Molecular Genetics, Dr. Dawid will speak about the molecular events that occur in embryonic cells soon after fertilization. During this time, known as gastrulation, the developmental fate of these cells is sealed, and they embark on a path along which they become increasingly dissimilar, diverse, and specialized.

To learn what triggers this differentiation process, he and his coworkers have identified and isolated from frog embryos genes that are among the first to become active in the

(See MIDER LECTURE, page 6)

CFC Victory Celebration Date and Place Changed

Please note the CFC victory celebration scheduled for Jan. 29 in the ACRF Amphitheater has been changed to Feb. 13 in the Masur Auditorium. The time remains 11 a.m.

Dr. Shulman Appointed New NIAMS Director

Dr. Lawrence E. Shulman has been appointed Director of the new National Institute of Arthritis and Musculoskeletal and Skin Diseases by Dr. James B. Wyngaarden, NIH Director.

As Director, Dr. Shulman will oversee the Federal Government's program for the conduct and support of biomedical research and research training in the broad areas of arthritis and musculoskeletal and skin diseases.

He has served as the Acting Director of NIAMS, since its establishment in the Department of Health and Human Services in April 1986. Prior to that time, he was director of the Division of Arthritis, Musculoskeletal and Skin Diseases at NIH.

Dr. Shulman came to the NIH in 1976 from Johns Hopkins University School of Medicine where he headed the arthritis research and education programs as director of the connective tissue division. When he joined NIH, one of his early responsibilities was to develop and implement the several diverse programs recommended in the "Arthritis Plan" presented to Congress that year by the National Commission on Arthritis and Related Musculoskeletal Diseases.

(See DR. SHULMAN, page 10)

NIAID Awards Contracts For Treatment Units

Contracts have been awarded to five medical centers for establishment of AIDS treatment evaluation units (ATEUs) by the National Institute of Allergy and Infectious Diseases. The contract proposals for these five units had been approved in June 1986, but at that time funding was available only for 14 ATEUs.

The new units will receive a total of $37.3 million over the next 4½ years to test experimental drugs in persons with acquired immune deficiency syndrome (AIDS), according to Dr. Anthony S. Fauci, NIAID Director. The patients will receive drugs that have potential for treatment of AIDS and the various opportunistic infections and cancers that develop in AIDS patients. AIDS has been diagnosed in more than 28,000 Americans since the first case was reported in 1981.

The five new ATEUs are located at Albert Einstein Medical Center in New York, N.Y.; Duke University in Durham, N.C.; Mt. Sinai Medical Center in New York, N.Y.; Tulane University in New Orleans, La.; and the University of Minnesota in Minneapolis. They will expand to 19 ATEUs the network established on June 30, 1986, when $100 million over 5 years was awarded to 14 institutions. □